OUR 9TH YEAR OF PROVIDING PROPRIETARY CAPITAL MARKETS INTELLIGENCE ON THE CANNABIS / HEMP / PSYCHEDELIC SECTORS
Quick
Links
More Charts
Credit Tracker By Industry Sector
Credit Tracker By Sector
Credit ratings are not currently available for public cannabis companies leaving companies, lenders and investors with a gap of information. The Viridian Cannabis Credit Tracker fills this gap. The model uses 11 market and financial statement variables to discern 4 key credit factors: Liquidity, Leverage, Profitability, and Size, to provide credit/liquidity analysis for over 370 public Cannabis/Hemp companies.
Week ended 08/18/2023
We are becoming concerned about liquidity in the Biotech/Pharma sector. The median free cash flow adjusted current ratio of the 46 companies in the sector is .02x; however, only 12 of the companies have solid liquidity of over 1x, while 23 have negative scores, indicating severe liquidity stress. Only two of the 46 companies had positive free cash flow for the most recent quarter, making the sector’s low median total liabilities/market cap of .44x somewhat deceptive. Still, the sector is further along than Psychedelics in producing revenue. Approximately ¼ of the companies had quarterly revenues above $1M.
Week ended 08/18/2023
We are becoming concerned about liquidity in the Biotech/Pharma sector. The median free cash flow adjusted current ratio of the 46 companies in the sector is .02x; however, only 12 of the companies have solid liquidity of over 1x, while 23 have negative scores, indicating severe liquidity stress. Only two of the 46 companies had positive free cash flow for the most recent quarter, making the sector’s low median total liabilities/market cap of .44x somewhat deceptive. Still, the sector is further along than Psychedelics in producing revenue. Approximately ¼ of the companies had quarterly revenues above $1M.
This Chart is Only Available to Higher Tier Memberships
Please Purchase a Premium or Enterprise membership to see more.
